anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nonalcoholic fatty liver disease (NAFLD) is a common liver disease in the United States. NAFLD can lead to severe liver disease in some patients. Patients with NAFLD develop resistance to the normal action of insulin. Insulin is important for processing sugar and fat and increased resistance to insulin leads to fat in the liver. There is a correlation between the amount of iron in a person's body and the ability of insulin to work properly. Several small studies suggest that removal of iron may improve both diabetes and NAFLD by lowering insulin resistance.

The goal of this pilot study is to determine the effect of iron depletion on insulin sensitivity in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. This study will be performed as an ancillary P\&F study to the NASH CRN; all participants will be recruited from the NASH CRN Database Study. Secondary outcome measures will include the effect of iron depletion on hepatic necroinflammation, markers of oxidative stress and intrahepatic fat content. Insulin resistance will be directly measured using a two-step hyperinsulinemic euglycemic clamp procedure, before and after iron depletion by phlebotomy. Oral glucose tolerance tests will also be performed in order to evaluate the efficacy of using the indirect, but less cumbersome, HOMA model to derive values of insulin resistance in this patient cohort. This study will advance our understanding of the role of body iron stores in the pathophysiology of type 2 diabetes mellitus and non-alcoholic fatty liver disease. If iron depletion results in improved insulin sensitivity, reduced hepatic necroinflammation and/or intrahepatic fat content, a large scale, randomized, controlled trial of iron depletion in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease will be planned.
The purpose of the present invention is to provide an identification assistance system, an identification assistance client, and an identification assistance method which make it possible for a user to accurately and easily identify a drug. Another purpose of the present invention is to provide an identification assistance server to be used in drug identification. According to one embodiment of the identification assistance system of the present invention, a first text which is the result of voice recognition is corrected, so voice recognition mistakes can be corrected. In addition, a drug search dictionary which has been caused to learn expressions used in drug classification is referenced to correct the first text, so an expression unique to drug classification can be taken into consideration. A user can execute a search by speaking not only a drug code and/or name, but also external appearance information. A search can be performed using external appearance information even if the code or the name is unknown.
Patients had The fixation method that involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Following surgery, the operated shoulder was supported with a triangular sling for a period of 4 to 6 weeks. Gentle mobilization was permitted once pain subsided, although full range of motion was limited due to pin impingement until implant removal.
After peaking in the third decade, bone mineral density (BMD) decreases slowly over time, with a more dramatic short-term decline at the time of menopause. Because of the association with osteoporosis and fracture, evaluation of BMD at the time of menopause is recommended, as is identification and treatment of any reversible causes of bone mineral loss. Most studies of women with endometriosis have shown no change or decreased BMD, while rats with induced endometriosis had a marked decrease in BMD. Often, studies in women did not control for factors that are known to affect bone density such as body mass index (BMI), exercise, or calcium intake. To address the question of whether endometriosis is associated with a change in BMD, we previously matched healthy volunteers and endometriosis patients for age, race, BMI, exercise level and calcium intake and compared BMD in the two groups. We found a decrease in BMD in women aged 40 - 50 who had a history of endometriosis, in comparison to women who did not have such a history. This study will expand that experience by studying more women aged 40 - 50 years with a history of endometriosis and matching them to women of the same race with similar age and BMI, who do not have a history of endometriosis. Participants will fill out a questionnaire about their medical, exercise and dietary history and will provide a single blood sample. A bone density study will be done and results will be made available to the participants.
Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of REBLOZYL or of other luspatercept products. 

In the BELIEVE trial, the median duration of exposure was 64 weeks, with a median ADA sampling period of 50 weeks. Of the 220 patients in the BELIEVE trial with beta thalassemia who require regular RBC transfusions treated with REBLOZYL and evaluable for the presence of anti-luspatercept-aamt antibodies, 4 patients (1.81%) tested positive for treatment-emergent anti-luspatercept-aamt antibodies, including 2 patients (0.9%) who had neutralizing antibodies detected. The majority of anti-luspatercept-aamt antibodies were of low titers. 

In the COMMANDS trial, the median duration of exposure was 42 weeks, with the median ADA sampling period of 27 weeks. In the MEDALIST trial, the median duration of exposure was 49 weeks, with the median ADA sampling period of 46 weeks. Of the 331 ESA-naïve (COMMANDS trial) and ESA-refractory or -intolerant (MEDALIST trial) patients with MDS who were treated with REBLOZYL, 21 patients (6.3%) tested positive for treatment-emergent anti-luspatercept-aamt antibodies, including 14 patients (4.2%) who had neutralizing antibodies. The majority of anti-luspatercept-aamt antibodies were of low titers. 

There were no severe acute systemic hypersensitivity reactions reported for patients with anti-luspatercept-aamt antibodies in REBLOZYL clinical trials, and there was no association between hypersensitivity type reaction or injection site reaction and presence of anti-luspatercept-aamt antibodies. There was no apparent effect of anti-luspatercept-aamt antibodies on clinical response.

Anti-Drug Antibody Effects on Pharmacokinetics

Among patients in the BELIEVE trial with luspatercept-aamt exposure data available, luspatercept‑aamt mean trough concentration (Ctrough) was approximately 35% lower in 4 patients with beta thalassemia who tested positive for treatment‑emergent anti‑luspatercept‑aamt antibodies (2.19 μg/mL) compared to patients with beta thalassemia who did not develop treatment‑emergent anti‑luspatercept‑aamt antibodies (3.38 μg/mL). There is insufficient data to assess whether the observed anti-luspatercept-aamt antibody associated pharmacokinetic changes reduce effectiveness in patients with beta thalassemia.

Among 21 ESA-naïve and ESA-refractory or -intolerant patients with MDS in the COMMANDS and MEDALIST trials who tested positive for treatment-emergent anti‑luspatercept‑aamt antibodies, there were no identified clinically significant effects of anti‑luspatercept‑aamt antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of luspatercept‑aamt over the treatment duration.
Part 2 will consist of two cohorts: Cohort A and Cohort B. Participants in both Cohorts with metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1.
Traumatic spinal cord injury (tSCI) resulting in quadriplegia is a life-altering injury for patients and caregivers. We conducted a retrospective review of patients treated for tSCI and quadriplegia at a level 1 trauma center to assess quality of life (QOL), socioeconomic factors, and mortality. Patients and caregivers were surveyed. Of the 65 patients included, 33 contacts were made. Seventeen surveys were completed (12 caregivers and 5 patients). Six unreachable patients were confirmed alive via medical record. Mortality rate among these 39 accessible patients was 23% (n = 9). Medicaid and uninsured patients experienced longer hospital length of stay (P < .0001) and discharged to home or nursing facilities (P < .0001) more often than those with private insurance or Medicare. Patients reported overall "good" QOL (80%) while caregivers reported overall decreased QOL markers. Our results reflect the resilience among this patient population, but also highlight the impact of this life-altering injury on the caregiver.
The present invention relates to traditional Chinese medicine preparation for treating coronary disease and angina pectoris, which is characterized in that the preparation is composed of multiple kinds of medicine such as ganoderma, ginseng, red sage root, eucommia bark, wolfberry fruit, prepared fleeceflower root, jujube seed, (sauted), schisandra, prepared rehmannia root, Chinese angelica, honey, etc. The preparation comprises preparation types of granular preparation, capsule preparation, tablet preparation, oral liquid preparation, syrup preparation, dripping pill preparation, etc. The present invention has the effects on nourishing blood and qi, tranquilizing hearts and nourishing mind. The present invention clinically treats 150 examples of angina pectoris, and a total effective rate is 96%. A total effective rate of electrocardiograms is 52.00%. The present invention better improves symptoms of Chinese medicine.
The first arm will receive Piperaquine tablets , that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
Objective. Monitoring of apnea of prematurity, performed in neonatal intensive care units by detecting central apneas (CAs) in the respiratory traces, is characterized by a high number of false alarms. A two-step approach consisting of a threshold-based apneic event detection algorithm followed by a machine learning model was recently presented in literature aiming to improve CA detection. However, since this is characterized by high complexity and low precision, we developed a new direct approach that only consists of a detection model based on machine learning directly working with multichannel signals.Approach. The dataset used in this study consisted of 48 h of ECG, chest impedance and peripheral oxygen saturation extracted from 10 premature infants. CAs were labeled by two clinical experts. 47 features were extracted from time series using 30 s moving windows with an overlap of 5 s and evaluated in sets of 4 consecutive moving windows, in a similar way to what was indicated for the two-step approach. An undersampling method was used to reduce imbalance in the training set while aiming at increasing precision. A detection model using logistic regression with elastic net penalty and leave-one-patient-out cross-validation was then tested on the full dataset.Main results. This detection model returned a mean area under the receiver operating characteristic curve value equal to 0.86 and, after the selection of a FPR equal to 0.1 and the use of smoothing, an increased precision (0.50 versus 0.42) at the expense of a decrease in recall (0.70 versus 0.78) compared to the two-step approach around suspected apneic events.Significance. The new direct approach guaranteed correct detections for more than 81% of CAs with lengthL≥ 20 s, which are considered among the most threatening apneic events for premature infants. These results require additional verifications using more extensive datasets but could lead to promising applications in clinical practice.
Cervical cancer remains a significant global health concern, particularly in low- and middle-income countries. While persistent infection with high-risk human papillomavirus (HR-HPV) is essential for cervical cancer development, it is not sufficient on its own, suggesting the involvement of additional cofactors. The human cytomegalovirus (HCMV) is a widespread β-herpesvirus known for its ability to establish lifelong latency and reactivate under certain conditions, often contributing to chronic inflammation and immune modulation. Emerging evidence suggests that HCMV may play a role in various cancers, including cervical cancer, through its potential to influence oncogenic pathways and disrupt host immune responses. This review explores clinical evidence regarding the co-presence of HR-HPV and HCMV in premalignant lesions and cervical cancer. The literature reviewed indicates that HCMV is frequently detected in cervical lesions, particularly in those co-infected with HPV, suggesting a potential synergistic interaction that could enhance HPV's oncogenic effects, thereby facilitating the progression from low-grade squamous intraepithelial lesions (LSIL) to high-grade squamous intraepithelial lesions (HSIL) and invasive cancer. Although the precise molecular mechanisms were not thoroughly investigated in this review, the clinical evidence suggests the importance of considering HCMV alongside HPV in the management of cervical lesions. A better understanding of the interaction between HR-HPV and HCMV may lead to improved diagnostic, therapeutic, and preventive strategies for cervical cancer.
LINZESS is contraindicated in patients less than 2 years of age. In nonclinical studies, deaths occurred within 24 hours in neonatal mice (human age equivalent of approximately 0 to 28 days) following oral administration of linaclotide which increased fluid secretion as a consequence of age-dependent elevated GC-C agonism resulting in rapid and severe dehydration (see Juvenile Animal Toxicity Data). 

A clinical GC-C ontogeny study in children 6 months to less than 18 years of age (N=99) was conducted to measure GC-C mRNA expression levels in duodenal and colonic samples to evaluate the risk of diarrhea and severe dehydration due to GC-C agonism. The results showed no age dependent trend in GC-C intestinal expression in children 2 to less than 18 years of age. There was insufficient data on GC-C intestinal expression to assess the risk of developing diarrhea and its potentially serious consequences in children less than 2 years of age [see Warnings and Precautions (5.1)].

The safety and effectiveness of LINZESS for the treatment of FC in pediatric patients 6 to 17 years of age have been established. Use of LINZESS for this indication is supported by evidence from adequate and well-controlled studies in adults and pediatric patients 6 years of age and older. The safety of LINZESS in adult and pediatric patients 6 to 17 years of age in clinical studies was similar [see Adverse Reactions (6.1) and Clinical Studies (14.3)]. 

The safety and effectiveness of LINZESS in patients with FC less than 6 years of age or in patients with IBS-C less than 18 years of age have not been established. 

Juvenile Animal Toxicity Data

In toxicology studies in neonatal mice, oral administration of linaclotide at 10 mcg/kg/day caused deaths on post-natal day 7 (human age equivalent of approximately 0 to 28 days). These deaths were due to rapid and severe dehydration produced by significant fluid shifts into the intestinal lumen resulting from GC-C agonism in neonatal mice [see Contraindications (4) and Warnings and Precautions (5.1)].

Tolerability to linaclotide increases with age in juvenile mice. In 2-week-old mice, linaclotide was well tolerated at a dose of 50 mcg/kg/day, but deaths occurred after a single oral dose of 100 mcg/kg. In 3-week-old mice, linaclotide was well tolerated at 100 mcg/kg/day, but deaths occurred after a single oral dose of 600 mcg/kg.
Although many susceptibility loci for IgA nephropathy (IgAN) have been identified, they only account for 11.0% of the overall IgAN variance. We performed a large genome-wide meta-analysis of IgAN in Han Chinese with 3616 cases and 10 417 controls to identify additional genetic loci of IgAN. Considering that inflammatory bowel disease (IBD) and asthma might share an etiology of dysregulated mucosal immunity with IgAN, we performed cross-trait integrative analysis by leveraging functional annotations of relevant cell type and the pleiotropic information from IBD and asthma. Among 8 669 456 imputed variants, we identified a novel locus at 4p14 containing the long noncoding RNA LOC101060498. Cell type enrichment analysis based on annotations suggested that PMA-I-stimulated CD4+CD25-IL17+ Th17 cell was the most relevant cell type for IgAN, which highlights the essential role of Th17 pathway in the pathogenesis of IgAN. Furthermore, we identified six more novel loci associated with IgAN, which included three loci showing pleiotropic effects with IBD or asthma (2q35/PNKD, 6q25.2/SCAF8, and 22q11.21/UBE2L3) and three loci specific to IgAN (14q32.32/TRAF3, 16q22.2/TXNL4B, and 21q21.3/LINC00113) in the pleiotropic analysis. Our findings support the involvement of mucosal immunity, especially T cell immune response and IL-17 signal pathway, in the development of IgAN and shed light on further investigation of IgAN.
BACKGROUND: Parents of children with epilepsy (CWE) are at increased risk of mental health difficulties including anxiety and depression, as well as sleep difficulties. From both the child's and parent's perspectives, health-related quality of life has been shown to be strongly related to parental mental health. However, there is no literature on parental sleep as a predictor of child health-related quality of life. The role of parental variables has been assessed in relation to epilepsy-specific variables (e.g., seizure severity, anti-seizure medications) and how these relate to health-related quality of life, but prior studies have failed to consider the role of co-occurring conditions which are prevalent in CWE. The current study aims to assess how common anxiety symptoms, depression symptoms and sleep problems are in parents of CWE; and to determine the impact these parental variables as well as child co-occurring conditions have on health-related quality of life in CWE.
METHODS: 33 CWE aged 4-14 years old were recruited from two hospitals and parents were asked to complete a series of questionnaires assessing both child and parental variables.
RESULTS: It was found that 33.3 % and 12.0 % of parents of CWE experienced clinically significant anxiety and depression symptoms respectively. In addition 67.9 % of parents presented with significant sleep problems. In initial analysis, parental anxiety symptoms, depression symptoms and sleep problems were all significantly predictive of child health-related quality of life. However when co-occurring child sleep problems and neurodevelopmental characteristics were included, parental variables were no longer significantly predictive of child health-related quality of life.
CONCLUSION: These results suggest that child co-occurrences mediate the relationship between parental variables and child health-related quality of life. The current data highlight the need for a systemic approach to epilepsy management and suggest that support for co-occurrences could benefit health-related quality of life for children and their parents.
The invention discloses a dual-purpose bottle which comprises a base plate, a first bottle and a second bottle. The first bottle comprises a first bottle body, a first piston, a first bottle opening and a first pressing spray nozzle. The internal volume space of the first bottle body is divided into a first liquid cavity and a first air cavity through the first piston. The second bottle comprises a second bottle body, a second piston, a second bottle opening and a second pressing spray nozzle. The internal volume space of the second bottle body is divided into a second liquid cavity and a second air cavity through the second piston. A ventilating port is formed between the first piston and the second piston, so that the first air cavity and the second air cavity are communicated with external atmosphere through the ventilating port. The invention further discloses a loading method of the dual-purpose bottle. The loading method comprises the steps that the first liquid cavity is filled with mosquito repellent liquid, and the second liquid cavity is filled with antipruritics. The dual-purpose bottle is filled with the mosquito repellent liquid and the antipruritics and is convenient to carry and use, and fast detumescence and itching relieving can be achieved through the antipruritics in the dual-purpose bottle.
<P>PROBLEM TO BE SOLVED: To provide a royal jelly extract which can exhibit an excellent estrogen-like action, to provide a method for producing the same, to provide an estrogen-deficient disease medicine containing the same, and to provide a food preparation containing the same.  <P>SOLUTION: This royal jelly extract is characterized by containing a substance exhibiting affinity with an estrogen receptor, namely a sterol compound, a steroid compound or a saccharide, in an amount of ≥1 wt. %. The method for producing the royal jelly extract comprises adding a royal jelly raw material to a separation carrier or resin or to an estrogen receptor-bound affinity carrier and then fractionating the extract. The estrogen-deficient disease medicine contains the royal jelly extract. The food preparation contains the royal jelly extract.  <P>COPYRIGHT: (C)2004,JPO